BRCA2 and triple-negative breast carcinoma: Combination benefit of AZD7648 and doxorubicin was also demonstrated in the triple-negative breast cancer (TNBC) patient-derived xenograft (PDX) model HBCx-17 (ATM WT, TP53 mutant, BRCA2 mutant, CCNE amplified, CDKN2A deleted), achieving 100% TGI while their respective single-agent treatments only induced 25% and 70% TGI (Fig. 4b).